UBS Group’s Phio Pharmaceuticals PHIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $32.9K | Buy |
26,987
+18,393
| +214% | +$21K | ﹤0.01% | 7628 |
|
|
2025
Q4 | $9.02K | Buy |
8,594
+8,581
| +66,008% | +$13.7K | ﹤0.01% | 8314 |
|
|
2025
Q3 | $32 | Buy |
+13
| New | +$30 | ﹤0.01% | 10070 |
|
|
2025
Q2 | – | Sell |
-103
| Closed | -$134 | – | 10699 |
|
|
2025
Q1 | $134 | Sell |
103
-2,294
| -96% | -$4.24K | ﹤0.01% | 9926 |
|
|
2024
Q4 | $4.32K | Buy |
2,397
+712
| +42% | +$1.94K | ﹤0.01% | 8765 |
|
|
2024
Q3 | $5.81K | Buy |
1,685
+1,413
| +519% | +$5.07K | ﹤0.01% | 8026 |
|
|
2024
Q2 | $1.69K | Buy |
272
+121
| +80% | +$791 | ﹤0.01% | 8523 |
|
|
2024
Q1 | $923 | Buy |
+151
| New | +$1.04K | ﹤0.01% | 8304 |
|
|
2023
Q2 | – | Sell |
-23
| Closed | -$1.16K | – | 9464 |
|
|
2023
Q1 | $1.16K | Sell |
23
-190
| -89% | -$10K | ﹤0.01% | 8793 |
|
|
2022
Q4 | $8.52K | Buy |
+213
| New | +$10.9K | ﹤0.01% | 8765 |
|
|
2022
Q2 | – | Sell |
-25
| Closed | -$2K | – | 10768 |
|
|
2022
Q1 | $2K | Sell |
25
-40
| -62% | -$3.81K | ﹤0.01% | 9656 |
|
|
2021
Q4 | $7K | Buy |
65
+7
| +12% | +$1.11K | ﹤0.01% | 9159 |
|
|
2021
Q3 | $13K | Buy |
58
+45
| +346% | +$9.4K | ﹤0.01% | 7677 |
|
|
2021
Q2 | $3K | Buy |
+13
| New | +$3.2K | ﹤0.01% | 8829 |
|
|
2021
Q1 | – | Sell |
-52
| Closed | -$15K | – | 9351 |
|
|
2020
Q4 | $15K | Buy |
52
+47
| +940% | +$11.9K | ﹤0.01% | 7170 |
|
|
2020
Q3 | $1K | Sell |
5
-98
| -95% | -$24.9K | ﹤0.01% | 7819 |
|
|
2020
Q2 | $24K | Buy |
103
+98
| +1,960% | +$23.5K | ﹤0.01% | 6435 |
|
|
2020
Q1 | $1K | Sell |
5
-3
| -38% | -$1.85K | ﹤0.01% | 7786 |
|
|
2019
Q4 | $427K | Buy |
8
+3
| +60% | +$3.45K | ﹤0.01% | 4980 |
|
|
2019
Q3 | $9K | Sell |
5
-1
| -17% | -$2.09K | ﹤0.01% | 7220 |
|
|
2019
Q2 | $14K | Buy |
6
+2
| +50% | +$5.25K | ﹤0.01% | 6852 |
|
|
2019
Q1 | $11K | Buy |
+4
| New | +$8.97K | ﹤0.01% | 6753 |
|
|
2018
Q4 | – | Hold |
0
| – | -$1K | – | 8225 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 7844 |
|
|
2018
Q2 | – | Sell |
-1
| Closed | -$14.8K | – | 7640 |
|
|
2018
Q1 | $12K | Buy |
+1
| New | +$23K | ﹤0.01% | 6764 |
|
|
2017
Q4 | – | Hold |
0
| – | – | – | 7100 |
|
|
2017
Q3 | – | Sell |
-1
| Closed | -$20K | – | 7922 |
|
|
2017
Q2 | $20K | Buy |
+1
| New | +$37K | ﹤0.01% | 6302 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 6619 |
|
|
2016
Q4 | – | Hold |
0
| – | -$16K | – | 7970 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 6474 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 7129 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 6930 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 8752 |
|
|
2015
Q1 | – | Hold |
0
| – | – | – | 9224 |
|
Other funds holding PHIO
VCM
VFT
HF
SRL
XT
UBS Group's PHIO Position: Q1 2026 in Review
UBS Group increased its Phio Pharmaceuticals (PHIO) stake by 214% in Q1 2026, buying an estimated $21K and bringing the position to 26,987 shares worth $32.9K. The position accounts for ﹤0.01% of the portfolio, ranked #7628.
UBS Group first reported a position in PHIO in Q2 2017 and has held it in 24 quarters since. The position peaked at $427K in Q4 2019. 24 funds tracked by Wall St. Rank hold PHIO as of Q1 2026.
- UBS Group held 26,987 shares of Phio Pharmaceuticals worth $32.9K as of Q1 2026.
- UBS Group bought 18,393 Phio Pharmaceuticals shares in Q1 2026, an estimated $21K.
- Phio Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7628 holding.
- UBS Group first reported a position in Phio Pharmaceuticals in Q2 2017 and has held it in 24 quarters since.
- UBS Group's Phio Pharmaceuticals position peaked at $427K in Q4 2019.
- 24 funds tracked by Wall St. Rank held Phio Pharmaceuticals as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.